HLA-B*27 — Frequency of clinical signs in Brazilian patients with spondyloarthritis

Ricardo Acayaba de Toledo a,b, Roberto Acayaba de Toledo b,c, Ulisses Camargo a, Ana Vitoria da Silveira Camargo a, Denise Haddad Xavier d, Mirella Fontana Batista d, Otávia Afonso Carneiro d, João Antônio de Camargos Pinto Robles a, Cinara Cássia Brandão de Mattos a, Octávio Ricci Júnior d,e, Luiz Carlos de Mattos a,d,*

a Immunogenetics Laboratory, Department of Molecular Biology, Medical School of São José do Rio Preto (FAMERP), São José do Rio Preto, São Paulo State, Brazil
b Rheumatology Outpatient Clinic, Hospital de Base of Regional Medical Faculty Foundation (HB-FUNFARME), São José do Rio Preto, São Paulo State, Brazil
c Department of Medicine I, Medical School of São José do Rio Preto (FAMERP), São José do Rio Preto, São Paulo State, Brazil
d Molecular Immunogenetics Laboratory, Regional Blood Center of São José do Rio Preto, Regional Medical Faculty Foundation (HEMOCENTRO-FUNFARME), São José do Rio Preto, São Paulo State, Brazil
e Department of Medicine II, Medical School of São José do Rio Preto (FAMERP), São José do Rio Preto, São Paulo State, Brazil

Received 6 June 2014; received in revised form 16 November 2014; accepted 17 November 2014
Available online 6 March 2015

KEYWORDS
HLA-B*27 gene; spondyloarthritis; spondyloarthropathy

Abstract  Spondyloarthritis presents clinical features, laboratory findings, and similar images, but their clinical manifestations reveal great heterogeneity in patients HLA-B*27 positive and negative. This study compared the frequencies of the clinical manifestations in the presence and absence of HLA-B*27. From the 156 patients with clinical suspicion of spondyloarthritis, 73 had a diagnosis of spondyloarthritis confirmed. The HLA-B*27 gene was identified by polymerase chain-reaction sequence-specific oligonucleotide probe (PCR-SSOP). The Student’s test was used to calculate the values of mean and the Fisher’s exact test was used to compare proportions. The values of odds ratio (OR) and confidence interval (CI) at 95% were also calculated (p < 0.05). The spondyloarthritis found were: ankylosing spondylitis (n = 47, 64.4%), psoriatic spondyloarthritis (n = 9, 12.3%), undifferentiated spondyloarthritis

* Corresponding author. Departamento de Biologia Molecular, Faculdade de Medicina de São José do Rio Preto — FAMERP, Avenida Brigadeiro Faria Lima, 5416, São José do Rio Preto, SP, CEP 15090-000, Brazil.
E-mail addresses: luiz.demattos@famerp.br, luiz.demattos@outlook.com (L.C. de Mattos).

http://dx.doi.org/10.1016/j.bgm.2014.11.002
2214-0247/© 2015, Taiwan Genomic Medicine and Biomarker Society. Published by Elsevier Taiwan LLC. All rights reserved.
Introduction

Spondyloarthritis is a group of diseases with common clinical, laboratory, and image findings. In this group fall ankylosing spondylitis, psoriatic spondyloarthritis, enteropathic spondyloarthritis (spondyloarthritis associated with Crohn’s disease or ulcerative colitis), reactive spondyloarthritis, and undifferentiated spondyloarthritis.\(^1\) These diseases are characterized by frequent inflammatory joint involvement of the sacroiliac joints (sacroilitis) and/or peripheral joints, predominantly oligoarthritis of large joints of the lower limbs. Ocular inflammatory lesions (uveitis), bowel (colitis nonspecific), or enthesitis (heel enthesitis) are additional findings in spondyloarthritis. Specific manifestations for each of the diseases belonging to the spondyloarthritis group are also frequently reported.\(^7\) Furthermore, spondyloarthritis is commonly associated with the HLA-B*27 gene, but the prevalence of this gene varies with each specific disease.\(^1\)\(^3\)

Different studies have analyzed the clinical manifestations of spondyloarthritis in patients with and without HLA-B*27, but the results revealed great heterogeneity. In a previous study, it was observed that the presence of this gene in patients with back pain increases the risk of sacroilitis by 50%.\(^4\) However, assessing the involvement of the hip joint in patients with spondyloarthritis, Burki and colleagues\(^8\) did not find association between this involvement and the presence of HLA-B*27. Also, another study reported no association between this gene and acute anterior uveitis in patients with spondyloarthritis.\(^4\) However, in another recent study, the authors reported that the occurrence of uveitis in patients with spondyloarthritis is an event common in patients carrying the HLA-B*27 gene.\(^7\) These data demonstrate the disagreement in the literature on the relationship between the clinical manifestations of spondyloarthritis and the HLA-B*27 gene. The aim of this study was to compare the frequencies of the main clinical signs of spondyloarthritis in the presence and absence of the HLA-B*27 gene.

Materials and methods

Ethical consideration

This cross-sectional study was approved by the Research Ethics Committee of Medical School of São José do Rio Preto (FAMERP), São José do Rio Preto (Case 055/2011) and each participant, after receiving all the information about the study objectives as well as on the procedures performed, signed the consent form.

Composition of the study groups

From June 2007 to May 2010, 156 patients with clinical suspicion of spondyloarthritis were referred to the Outpatient Clinic of Rheumatology from the Regional Medical Faculty Foundation (FUNFARME). All of them were investigated for the presence or absence of the HLA-B*27 gene at the Immunogenetics Laboratory of the Molecular Biology Department from Medical School of São José do Rio Preto (FAMERP). Overall, 73 patients had a clinical diagnosis of spondyloarthritis confirmed according to the criteria of the European Study Group Spondyloarthropathy (ESSG) used at the time.\(^8\) Clinical information was obtained from the medical records of patients.

Blood sampling and genomic DNA extraction

A sample of 5 mL of peripheral blood was collected in tubes with EDTA from each individual by venipuncture. The genomic DNA was extracted from the white blood cells using a commercial kit (PureLink, Invitrogen\(^9\), Carlsbad, CA, USA).

HLA-B*27 genotyping

The HLA-B*27 genotyping was performed by polymerase chain reaction-specific sequence oligonucleotide (PCR-SSO) in a low resolution system (One Lambda INC, Canoga Park, CA, USA) with Luminex technology. The manufacturer’s recommendations were strictly followed.

Statistical analysis

The data were compared using Fisher’s exact test (Graph-Pad Instat version 3.06, GraphPad Software, Inc., La Jolla, CA, USA). The mean values for age were calculated by the Student t test. Odds ratio (OR) and confidence interval (CI) of 95% values were also calculated. A p value ≤ 0.05 was considered significant.
Results

Of the 73 selected patients, 53 (72.6%) were male and 20 (27.4%) female. The mean age for the whole casuistic was 48.7 ± 12.2 years and did not differ between the genders (p = 0.320). The median for the whole casuistic was 48 years, ranging from 20 years to 80 years. The distribution of the five spondyloarthritis between genders did not present statistically significant differences (Table 1).

Table 1 shows the frequencies of gender and the spondyloarthritis according to the presence (n = 35, 47.9%) or absence (n = 38, 52.1%) of the HLA-B*27 gene. The HLA-B*27 gene was more frequent in males (30/53; 56.6%) than in females (5/20; 25.0%). Ankylosing spondylitis was more frequent in males who were HLA-B*27 positive (26/30; 86.6%) than in females who were HLA-B*27 positive (3/5; 60.0%; OR: 10.833, 95% CI: 2.382–49.261, p = 0.001; data not shown). The values of OR highlight the importance of the presence of this gene as a risk factor for ankylosing spondylitis in males.

Table 2 shows the frequencies of the clinical signs in patients with and without HLA-B*27. The mean age at onset of symptoms was 39.1 ± 11.7 years and did not differ between the genders (p = 0.905). A strong association between bilateral sacroiliitis and the HLA-B*27 gene was observed for ankylosing spondylitis in comparison to other spondyloarthritis (OR: 5.294, 95% CI: 1.474–19.018, p = 0.009; data not shown in table). The values of OR highlight the importance of the presence and absence of the HLA-B*27 gene with the clinical signs of radiological sacroiliitis (p = 0.014) and intestinal involvement (p = 0.048) among patients suffering from different spondyloarthritis, respectively.

Discussion

The aim of this study was to compare the frequencies of the main clinical signals used as criteria for the diagnosis of spondyloarthritis according to the ESSG, in patients with and without HLA-B*27. A sample of patients from the northwestern region of São Paulo, Brazil characterized by the influence of a European background were analyzed. The criteria of the ESSG were adopted for the diagnosis of the spondyloarthritis investigated in this study, since they include clinical, laboratory, imaging, and the presence of HLA-B*27. These criteria are considered indicators of good sensitivity and specificity in the diagnosis of this group of diseases.

The HLA genotyping method used in this study is universally recognized as a good tool for characterization of
HLA polymorphisms. It has been extensively used for matching transplant recipients and donors and for genomic wide association studies. It allows the identification of the HLA-B*27 alleles and the determination of homozygous and heterozygous genotypes with a better level of resolution in comparison with serological methods used in the past, which presented some limitations.15 Recently, we used this method to determine the frequencies of HLA Class I and Class II genes among voluntary bone marrow donors from the northwestern region of São Paulo.16

The HLA-B*27 gene presented a high frequency in our casuistic, but it was prevalent among those suffering from ankylosing spondylitis. Also, it was prevalent in male patients in comparison to female patients. Despite these differences, there were no statistically significant differences between genders with respect to the frequencies of the six spondyloarthritis analyzed in this study. These data agree with those published by the Ibero-American Registry of Spondyloarthritis (RESPONDIA) Study Group for Brazilian patients and suggest that the frequencies of spondyloarthritides diagnosed in the northwest of São Paulo did not differ from those reported for other regions of Brazil.17 These observations highlight the clinical importance of the HLA-B*27 gene as an important immunogenetic risk factor for spondyloarthritis.

The presence of spondyloarthritis was approximately three times higher in men than in women while the average age of onset of symptoms did not differ between the genders. The most frequent spondyloarthritis was ankylosing spondylitis, followed by psoriatic spondylarthid, and undifferentiated spondyloarthritis. The enteropathic spondyloarthritis and reactive arthritis appeared less frequently. These data are in agreement with those reported by Gallinaro and colleagues17 for Brazilian patients. In view of these observations, it can be assumed that if there are other selective genetic or environmental factors in nature acting in the genesis of this group of diseases in the region where this study was conducted, they do not seem to modify the frequency of spondyloarthritis commonly diagnosed in the population.

Ankylosing spondylitis, as expected, was positively associated with the HLA-B*27 gene. The molecular bases underlying this association are not fully understood. However, studies with transgenic animal models show that the HLA-B*27 gene plays an important role in the genesis of ankylosing spondylitis, but due to the complexity of the disease, this gene is the only one among several genes that determines predisposition and phenotypic variations of this disease.3 It is possible that incorrect folding and dimerization of the z chain of HLA-B27 glycoprotein in the endoplasmic reticulum, allied to the high expression of interleukin-23 (IL-23) the polymorphisms of its receptor (IL-23R) contribute to susceptibility to ankylosing spondylitis.3,14–16 These observations support the view that ankylosing spondylitis is a complex disease and although its clinical variability can be influenced by other genes, the HLA-B*27 gene occupies a prominent position as a marker of susceptibility to this form of spondyloarthritis.16

The enteropathic spondyloarthritis was negatively associated with the HLA-B*27 gene, including those patients with manifestations of sacroiliitis. These observations disagree with a previous study18 but are consistent with others that have shown the absence of the HLA-B*27 gene in the majority of patients with inflammatory bowel disease associated with spondyloarthritis.19–22 The reasons for this negative association are not fully understood, but it is possible that ethnicity contributes to the different clinical manifestations of spondyloarthritis in Brazilian casuistic.23

In fact, the population of the northwestern region of São Paulo has a strong Italian, Spanish, Portuguese, and Arabic genetic background, while the sample of Protzer and colleagues,18 is primarily of German origin. Furthermore, it is possible that the absence of the HLA-B*27 gene exerts a less modulator effect on the genesis of sacroiliitis in the enteropathic spondyloarthritides and that other genes which contribute to modulation of the autoimmune response in this form of spondyloarthritis.24

This study noted that radiological sacroiliitis is associated with the HLA-B*27 gene independent of the type of the spondyloarthritides, but it was stronger for patients with ankylosing spondylitis. This association is explained at least in part by the strong influence of this gene in the pathogenesis of ankylosing spondylitis. The observation that the

---

**Table 3** Main clinical signs in 73 Brazilian patients with different spondyloarthritis according to positivity for the HLA-B*27 gene.

<table>
<thead>
<tr>
<th>Main clinical signs</th>
<th>n</th>
<th>HLA-B*27 (+) n (%)</th>
<th>HLA-B*27 (−) n (%)</th>
<th>OR (95%CI) p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Axial pain</td>
<td>60</td>
<td>31 (51.7)</td>
<td>29 (48.3)</td>
<td>2.405 (0.667–8.671) 0.226</td>
</tr>
<tr>
<td>Radiological sacroiliitis</td>
<td>63</td>
<td>34 (53.9)</td>
<td>29 (46.1)</td>
<td>10.552 (1.260–88.256) 0.014*</td>
</tr>
<tr>
<td>Synovitis</td>
<td>27</td>
<td>12 (44.4)</td>
<td>15 (55.6)</td>
<td>0.800 (0.308–2.078) 0.808</td>
</tr>
<tr>
<td>Family history</td>
<td>4</td>
<td>3 (75.0)</td>
<td>1 (25.0)</td>
<td>3.469 (0.343–35.039) 0.344</td>
</tr>
<tr>
<td>Psoriasis</td>
<td>10</td>
<td>2 (20.0)</td>
<td>8 (80.0)</td>
<td>0.227 (0.044–1.156) 0.088</td>
</tr>
<tr>
<td>Intestinal involvement</td>
<td>11</td>
<td>2 (18.2)</td>
<td>9 (81.8)</td>
<td>0.195 (0.038–0.978) 0.048*</td>
</tr>
<tr>
<td>Pain in the buttocks</td>
<td>10</td>
<td>3 (30.0)</td>
<td>7 (70.0)</td>
<td>0.415 (0.098–1.753) 0.312</td>
</tr>
<tr>
<td>Enthesitis</td>
<td>4</td>
<td>3 (75.0)</td>
<td>1 (25.0)</td>
<td>3.469 (0.343–35.039) 0.344</td>
</tr>
<tr>
<td>Diarrhea 1 mo before</td>
<td>1</td>
<td>0 (0.0)</td>
<td>1 (100)</td>
<td>0.352 (0.013–8.938) 1.000</td>
</tr>
<tr>
<td>Urethritis</td>
<td>1</td>
<td>1 (100)</td>
<td>0 (0.0)</td>
<td>3.438 (0.131–84.990) 0.475</td>
</tr>
</tbody>
</table>

* p < 0.05 indicates significance, calculated by Fisher’s exact test. + = presence; −, absence.
severity and the number of sacroiliac lesions correlate strongly with the HLA-B*27 gene substantiate the proposition that ankylosing spondylitis begins in the sacroiliac joints and progresses to the spine. However, it is not clear how the HLA-B*27 gene contributes to bilateral sacroiliitis in other spondyloarthritides. In fact, a minor proportion of patients with other spondyloarthritides carrying bilateral sacroiliitis and the HLA-B*27 gene were observed in this study. As the direct effect of this gene on the origin and evolution of sacroiliitis still remains unclear, this topic deserves much more investigation.

This study also observed a marginal association between intestinal involvement and the absence of the HLA-B*27 gene and these data confirm observations previously reported. It is possible that this negative association obscures the radiological manifestations in patients, who displaying other genetic predisposition factors, have sacroiliitis and intestinal injury even in the absence of HLA-B*27. Half of the patients analyzed here, carrying the enteropathic form of the disease, presented clinical and radiological signs of sacroiliitis, but they were HLA-B*27 negative. This observation agrees with the proposition that the presence of sacroiliitis in enteropathic spondyloarthritis is an isolated phenomenon and not related to the HLA-B*27 gene.

All of the six patients with enteropathic spondyloarthritis analyzed in this study first developed inflammatory bowel disease and then had joint involvement. Furthermore, of the 11 patients with intestinal involvement, regardless of diagnosis, nine were HLA-B*27 negative. The reasons for this sequence of events are not fully understood, but it is possible that the HLA-B*27 gene has a lower effect in modulating the intestinal autoimmune response in comparison with that affecting the joints, mainly the axial spine.

The data presented here must be viewed with caution due to the small number of patients enrolled and therefore these results should be taken as preliminary. Similar studies enrolling greater sample sizes and composed of other ethnic and mixed casuistic in Brazil may contribute to confirming our findings.

Conclusion

In conclusion, we observed that the HLA-B*27 gene was more prevalent in patients with ankylosing spondylitis, but not in those with enteropathic spondyloarthritis. The image signals of sacroiliitis were associated with the presence of this gene, whereas the intestinal involvement was associated with its absence.

Conflict of interest

All the authors declare that they do not have financial disclosure or conflicts of interest.

Acknowledgments

This study was supported by the Institutional School of Medicine Grant BAP-FAMEP 4287/2012, by the Brazilian Ministry of Science, Technology and Innovation PIBIC-CNpq Scholarship, and partially by São Paulo Research Foundation FAPESP #2012/20735-2. The opinions, assumptions, and conclusions or recommendations expressed in this material are the responsibility of the authors and do not necessarily reflect the views of FAPESP.

References


